Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03659357
Other study ID # TJ-IRB20180508
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date September 1, 2018
Est. completion date September 30, 2021

Study information

Verified date September 2019
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Purpose: To compare the accuracies of computed tomographic (CT) enterography and magnetic resonance (MR) enterography for the detection and radiomics characterization of small-bowel tumors (including gastrointestinal stromal tumors, adenomas and lymphomas, etc); Hypothesis: MR enterography was noninferior to CT enterography for the diagnosis and evaluation of small bowel tumors in generally well-distended small bowel.


Description:

The investigators will conduct a 36-month clinical trial, the specific process is as follows:

1. Incorporate patients with the above criteria, communicate with the participants to make informed consent and sign informed consent;

2. It is recommended that the attending physician issue the corresponding MRE checklist and the CTE checklist and make an appointment to check the same day to remind the patient to perform the corresponding bowel preparation work in advance, and perform renal function tests within 3 days before the examination;

3. The enrolled patients were measured for height and weight, and the BMI was calculated. CTE and MRE were performed according to the results of balanced randomization. The MRE was performed on a 3.0T MRI scanner; the CTE examination was performed on a 320-row CT scanner, and the iodine-containing contrast agent was administered according to the patient's height and weight and GFR;

4. Both examinations require an empty stomach preparation (more than 4 hours), and oral (1500ml) 2.5% mannitol aqueous solution before the examination to ensure intestinal filling, subcutaneous indwelling needle preparation, in order to save patient examination time, so the two examinations are completed within 6 hours, before the second inspection, you need to add 150-300ml of 2.5% mannitol aqueous solution;

5. The images obtained were evaluated by two imaging physicians for lesions, numbers, size changes, density/signal values, and peripheral tissue lesions obtained by the two methods;

6. After the patient has obtained a definitive diagnosis according to the routine medical procedure, the above imaging diagnosis results are compared with the confirmed diagnosis results.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 150
Est. completion date September 30, 2021
Est. primary completion date September 30, 2020
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with clinical suspicion of small intestinal neoplasms and prescribed CTE and/or MRE examinations;

- Age/sex: unlimited;

- Patients with no severe heart, liver, kidney insufficiency;

- Patients who voluntarily participate in clinical trials and sign written informed consent.

Exclusion Criteria:

- patients with heart and liver insufficiency;

- patients with pacemakers installed and which materials are unknown, and patients with metal implants in the body, and nerve stimulators;

- patients who are allergic to iodine and intestinal contrast agents;

- pregnant women, patients with acute or chronic renal failure and hemodynamic instability;

- patients unable to tolerate adequate breath holding for complete CT or MR examination;

- patients who can not maintain compliance and cannot strictly implement the plan.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Yaqi Shen Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the size in centimeters the size of the small bowel tumor through study completion, an average of 3 years, the size of the small bowel tumor will be reported.
Secondary volume in cm^3 the volume of the small bowel tumor through study completion, an average of 3 years
Secondary intensity of the neoplasms measured in the MRE the intensity of the small bowel tumor measured in the MRE, and it is graded into low, moderate and high. through study completion, an average of 3 years
Secondary intensity of the neoplasms measured in the CTE in Hu the intensity of the small bowel tumor measured in the CTE through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Enrolling by invitation NCT06048146 - A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis N/A
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Recruiting NCT03303495 - A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC Phase 3
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT03271255 - Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) Phase 2
Completed NCT02785783 - Endoringsā„¢ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection N/A
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03280407 - NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT01995942 - Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Active, not recruiting NCT02202928 - Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer Phase 2
Not yet recruiting NCT05193292 - Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer Phase 2
Recruiting NCT04755920 - SGM-101 in Colorectal Brain Metastases. Phase 2
Completed NCT03072472 - BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities N/A
Completed NCT01996306 - A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC Phase 3
Active, not recruiting NCT02005965 - Low Rectal Cancer Study (MERCURY II)